A Randomized, Phase IIIb, Two-period , Double-blind, Two-treatment, Chronic-dosing (7 Days), Single-center Crossover Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease, Compared With Placebo

This is a randomized, double-blind, placebo-controlled, single-center, chronic-dosing (7
days), two-period, two-treatment, cross-over study to evaluate the treatment effect of PT003
compared with that of Placebo MDI on Cardiovascular Hemodynamics following chronic-dosing (7
days) in subjects with moderate to severe COPD.